Majority of Brits shower in the morning NOT the evening, survey finds
A poll of 2,000 adults found early washes are more popular, with 57 per cent of those with a preference favouring the morning.
1
In comparison, only 32 per cent prefer to get lathered up before bed.
One in 10 (11 per cent) opted for neither option, preferring to get clean at some point in the afternoon.
The main reasons for preferring an early morning spritz included wanting to start the day clean and refreshed (70 per cent), helping them wake up in the morning (50 per cent), and getting energised for the day ahead (45 per cent).
A morning shower even formed part of the top three things to help people get ready for the day, alongside having a cup of coffee (34 per cent) and a healthy breakfast (29 per cent).
A spokesperson for Utilita Energy, which commissioned the research as part of its Power Price List series – a cost to run database of all household appliances, said: 'Heating up water to shower consumes a lot of energy, so we were interested to better understand people's behaviours.
'The smart meter data we see from Utilita households sees a spike in the morning and again in the afternoon and evening – clearly showers contribute more to the morning spike than the ones later in the day.'
Despite winning the debate, morning showers were found to be a slightly more rushed and a less relaxing affair – with the average person spending an additional two minutes under the water in the evening than they do first thing.
Nearly four in 10 also voted night-time cleanses as more relaxing, compared to only 15 per cent claiming this of morning washes.
With top reasons for opting for an evening shower related to its soothing effects, with four in 10 using this time to unwind and de-stress before they turn in for the night.
While 51 per cent think showering before bed helps them to sleep more soundly, according to OnePoll.com data.
'Smells great,' Dollar Tree fans cry after spotting $1.25 Sol de Janeiro dupe on shelves – it's $30 less than original
Timesaving also contributed to these night owls' preferences, who use their extra time in the morning to sleep in (24 per cent) or devote time to other things (22 per cent).
It also emerged 28 per cent claim a shower in the morning is vital to their routine, with 17 per cent saying the same about an evening clean.
One in 10 even said they would be unlikely to rinse and repeat if they couldn't do so at their preferred time.
Top reasons for making changes to their routine included getting ready for a special occasion (36 per cent), travel plans (28 per cent), and oversleeping (24 per cent).
Utilita's spokesperson added: 'The cost of running a shower for eight minutes is around 32p on average – or £116 a year.
"The Power Price List is designed to reveal how tweaking habits can provide sizeable savings for households.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
21 minutes ago
- The Independent
Pharmacy warning of unsustainable demand for weight loss medication
The National Pharmacy Association (NPA) has issued a warning that the burgeoning demand for weight loss injections may be unsustainable, citing a significant mismatch between public interest and clinical suitability for the treatments. The NPA, which represents over 6,000 independent community pharmacies, highlighted this concern. A poll commissioned by the association revealed that 21 per cent of respondents had attempted to access weight loss treatments in the past year, either online or directly from a pharmacy. This figure surged to 35 per cent among 16 to 34-year-olds, contrasting sharply with just seven per cent of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'
Reuters
an hour ago
- Reuters
Roche to investigate whether new drug can delay or prevent Alzheimer's disease
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, it said on Sunday, as a part of the company's growing development programme for the disease. The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer's, Roche said in a statement. Trontinemab is designed so that the drug is transported across the blood brain barrier—protective blood vessels that prevent chemicals in the bloodstream from entering the brain — in hopes of delivering more of the treatment to the brain. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently, with Lilly's drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the U.S. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi and Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They carry hefty price tags as well as the risk of serious brain swelling and bleeding.
Reuters
2 hours ago
- Reuters
Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, Bloomberg News reported on Sunday. The new late-stage study will target people who are at risk of cognitive decline and aim to slow down the emergence of symptoms or prevent them fully, the report said, citing a statement. The new pre-clinical study is the third largest late-stage trial that the company has announced for its drug trontinemab, which uses an experimental technology called brain shuttle to ferry medicine past the protective blood-brain barrier, according to the report. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently with Lilly's Alzheimer's drug Kisunla getting recommendation from the European Medicines Agency (EMA) last week. Reuters could not immediately verify the report. Roche did not immediately respond to a request for a comment. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi, and Eli Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They also carry hefty price tags and the risk of serious brain swelling and bleeding.
